ArticleJournal of clinical microbiology2023
Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test.
Open access · greenAbstract readMulticenter Study
In one paragraph
Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC-antimicrobial resistance · 2026Review
- Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales.Journal of clinical microbiology · 2026Article
- A multicenter performance evaluation of aztreonam-avibactam gradient diffusion susceptibility testing forJournal of clinical microbiology · 2026Article
- Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producingMicrobiology spectrum · 2026Article
- Comparison of agar-based methodologies to broth disc elution for the detection of aztreonam susceptibility in the presence of ceftazidime-avibactam.Microbiology spectrum · 2026Article
- Management of an infection from NDM-1-producingASM case reports · 2026Article
- Sulbactam-durlobactam in combination with aztreonam and carbapenems against carbapenem-resistantJournal of clinical microbiology · 2025Article
- Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due toAntimicrobial agents and chemotherapy · 2025Article
- Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.Antimicrobial agents and chemotherapy · 2025Article
- Therapeutic challenges in managingFrontiers in cellular and infection microbiology · 2025Review
- Evaluation of the KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit and Carbapenem-Resistant K.N.I.V.O. Detection K-Set in detecting KPC variants.Journal of clinical microbiology · 2024Article
- Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales.Journal of clinical microbiology · 2024Article
- The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.Antimicrobial agents and chemotherapy · 2024Article
- Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam againstMicrobiology spectrum · 2024Article
- Evaluation of the in vitro activity of ampicillin-sulbactam and cefoperazone-sulbactam against A. Baumannii by the broth disk elution test.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Prevalence of ST1049-KL5 carbapenem-resistant Klebsiella pneumoniae with a blaCommunications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Harley HarrisDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Lili TaoDepartment of Pathology, Microbiology, and Immunology, Division of Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Emily B JacobsDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yehudit BergmanDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ayomikun AdebayoDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Tsigedera TekleDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Shawna LewisDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ashley DahlquistCollege of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
Taylor C AbbeyCollege of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
Eric WenzlerCollege of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
Romney HumphriesDepartment of Pathology, Microbiology, and Immunology, Division of Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-6568-156X
Patricia J SimnerDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6134-151X
Johns Hopkins University · USUniversity of Illinois Chicago · USVanderbilt University Medical Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to limited therapeutic options, there is a clinical need to assess the
Indexed as
Anti-Bacterial AgentsAztreonamAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug CombinationsGram-Negative BacteriaHumansMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug Combinationsantimicrobial susceptibility testingaztreonambroth disk elutionceftazidime-avibactamCLSImulticenter study
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.